Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.

@article{Woods2006CuringCA,
  title={Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.},
  author={William G A Woods},
  journal={Pediatric blood & cancer},
  year={2006},
  volume={46 5},
  pages={565-9}
}
Childhood and adolescent acute myeloid leukemia (AML) is traditionally one of the hardest childhood cancers to successfully treat and had an overall survival well under 10% in the 1960s. Initial progress was made by three major events: (1) active chemotherapeutic agents were identified which led to remissions for the first time in this disease; (2) cooperative groups were instituted leading to important clinical trials; and (3) several single institutions began experimenting with the role of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.

Molecular therapy : the journal of the American Society of Gene Therapy • 2016

Similar Papers

Loading similar papers…